Skip to content


    DAE Class; Rx

    Common Brand Names; Psorcon, ApexiCon, ApexiCon E

    • Corticosteroids, Topical

    High potency, topical, fluorinated corticosteroid
    Used to treat corticosteroid-responsive dermatoses and psoriasis
    Long-term or extensive use can lead to systemic side effects

    Indicated for the treatment of corticosteroid-responsive dermatoses, including atopic dermatitis, localized vitiligo, eczema, phimosis, lichen planus, and localized bullous pemphigoid. 

    For the treatment of psoriasis.


    Apply sparingly to affected area(s) qDay-q8hr; discontinue therapy when; discontinue therapy if control achieved and reassess diagnosis if no improvement within 4 weeks

    Underlying infection


    Ophthalmic use

    Skin atrophy




    Secondary infection


    Pigmentation changes

    HPA suppression (with higher potency used >2 wk)





    Acneiform eruptions


    Perioral dermatitis

    Allergic contact dermatitis

    Maceration of the skin,


    Postmarketing Reports

    Vision Disorders: Cataract, glaucoma, central serous chorioretinopathy

    Chronic topical corticosteroid therapy may interfere with growth and development in children

    Use med to very high potency for <2 wk to reduce local and systemic side effects

    Use low potency for chronic therapy

    Kaposi’s sarcoma reported with prolonged corticosteroid therapy

    Avoid medium to very high potency on face, folds, groin because can increase steroid absorption

    Use lower potency for children (ie, increase BSA/kg, therefore increase systemic absorption)

    Use of topical corticosteroids may increase risk of posterior subcapsular cataracts and glaucoma; cataracts reported in postmarketing experience with use of topical diflorasone diacetate products; glaucoma, with possible damage to optic nerve, and increased intraocular pressure reported in postmarketing experience with use of topical dermal corticosteroids

    Avoid contact with eyes; advise patients to report any visual symptoms

    Some patients, including children may exhibit susceptibility to corticosteroid-induced HPA axis suppression and Cushing’s syndrome due to prolonged use, or addition of occlusive dressings

    Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity

    If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted

    In presence of dermatological infections, institute appropriate antifungal or antibacterial; if a favorable response does not occur promptly, the discontinue corticosteroid therapy until infection has been adequately controlled


    Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels; more potent corticosteroids shown to be teratogenic after dermal application in laboratory animals; there are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids; topical corticosteroids should be used during pregnancy only if potential benefit justifies potential risk to fetus; drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time


    Not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk; because many drugs are excreted in human milk, exercise caution should when administering product to a nursing woman


    50 g/week topically.


    50 g/week topically.


    50 g/week topically.


    10 g/week topically.



    • 0.05%